Search

Find what you’re looking for

3287 results

Nouryon starts production of new dibenzoyl peroxide in Mexico

Nouryon (formerly AkzoNobel Specialty Chemicals) has started production of a new version of its dibenzoyl peroxide (BPO), Perkadox GB-50, at Los Reyes, Mexico. It is the first dry BPO on the market that does not use the desensitizing agent dicyclohexyl phthalate (DCHP), which the European Union recently reclassified as a category 1B Reproductive Toxin.

https://www.nouryon.com/news-and-events/news-overview/2019/nouryon-starts-production-of-new-dibenzoyl-peroxide-in-mexico/

Nouryon strengthens US Expancel position with new Midwest production facility

Nouryon has selected Green Bay, Wisconsin, US as the location for a new facility to produce its Expancel expandable microspheres. The expansion project, which was announced last year, strengthens the company’s position in expandable microspheres, which are used to make customers’ end products lighter and reduce costs.

https://www.nouryon.com/news-and-events/news-overview/2020/nouryon-strengthens-us-expancel-position-with-new-midwest-production-facility/

Nouryon to build Bermocoll facility in Southeast Asia to meet global demand in Paints and Coatings end-market

Nouryon plans to build a new production facility to meet the increasing global demand for innovative and sustainable additives for the rapidly growing Paints and Coatings end-market and other high-growth end-markets.

https://www.nouryon.com/news-and-events/news-overview/2021/nouryon-to-build-bermocoll-facility-in-southeast-asia-to-meet-global-demand-in-paints-and-coatings-end-market/

Nouryon to double capacity of Kromasil® chromatography media in Sweden to meet growing demand for peptide-based diabetes and obesity treatments

Nouryon today announced the expansion of its Kromasil® chromatography media manufacturing facility in Bohus, Sweden. Construction will begin in early 2025, and the start of production is expected in early 2027. This expansion will double the facility’s capacity to meet the growing global demand for peptide-based drugs in the GLP-1 receptor agonist class. Kromasil® chromatography media, a key product in the Company's Consumer & Life Sciences segment, plays a crucial role for purifying novel peptide-based pharmaceuticals, including treatments for type 2 diabetes and obesity.

https://www.nouryon.com/news-and-events/news-overview/2025/nouryon-to-double-capacity-of-kromasil-chromatography-media-in-sweden-to-meet-growing-demand-for-peptide-based-diabetes-and-obesity-treatments/

We respect your privacy.

We use essential and non-essential cookies to provide, secure, analyze and improve our services. Click 'Agree' to accept or learn more about our Cookie Policy and edit your preferences. 

You can change settings at any time.

Edit